Although the TPR-MET fusion was first identified, [27] a ST7-MET fusion was reported as an acquired resistance mechansim to the third-generation TKI lorlatinib in a NSCLC patient with dual ALK-MET aberrations [28]. Here, MET is linked to non-small cell lung carcinoma.